Jul. 8 at 9:02 PM
$POAI The
$10 million SEPA with Yorkville Advisors Global (who has a reputation much like H.C.Wainwright) significantly reduces Predictive Oncology’s Nasdaq delisting risk by providing funds to address the equity shortfall, potentially securing compliance by mid-2025. However, it does not directly resolve the minimum bid price issue, and dilution from share issuances could exacerbate this challenge. On the share price, the SEPA introduces short-term downward pressure due to dilution fears, as evidenced by the 4.7% drop today, but on the other hand it offers long-term upside if the funds drive meaningful progress in AI-driven drug discovery. Investors should monitor the company’s share issuance strategy, operational performance, and Nasdaq compliance efforts to gauge the SEPA’s ultimate impact. But given the history of POAI and the lawsuit from Renovaro - it looks a bit sketchy
